Table 1.
Target | Representative to | Conjugateda | Isotype control | Clone | Species | Concentration | Company |
---|---|---|---|---|---|---|---|
CD11b, | Leukocytes | PE-Cy7, PE or none | IgG2b κ | M1/70 | Rat | 2 μg/mL | BD Pharmingen |
Ly6C, | Monocytes | PE0Cy7, PE or none | IgM κ | AL-21 | Rat | 2 μg/mL | BD Pharmingen |
Ly6G, | Neutrophils | PE or none | IgG2a κ | 1A8 | Rat | 2 μg/mL | BD Pharmingen |
F4/80, | Macrophages/Kupffer cells | PE or none | IgG2a κ | BM8 | Rat | 2 μg/mL | BioLegend |
CD3e, | T cells | none | IgG1 κ | 145-2C11 | Hamster | 20 μg/mL | BD Pharmingen |
CD19 | B cells | none | IgG2a κ | 1D3 | Rat | 2 μg/mL | BD Pharmingen |
Bpb | none | IgG1 | polyc | Rat | 30 μg/mL | Ref. (52) | |
CD45, | Leukocyte common antigens | PE | IgG2a κ | MEC13.3 | Rat | 2 μg/mL | BD Pharmingen |
CD16/32 | Phagocytic cells | PE-Cy | IgG2b κ | 2.4G2 | Rat | 2 μg/mL | BD Pharmingen |
CD34 | Stem cells | PE | IgG2a κ | RAM34 | Rat | 2 μg/mL | BD Pharmingen |
CD115 | Phagocytic precursor | PE | IgG1 κ | T38-320 | Rat | 5 μg/mL | BD Pharmingen |
CD14 | Monocytes/macrophages | PE | IgG1 κ | rmC5-3 | Rat | 2 μg/mL | BD Pharmingen |
CD150 | Lymphoid cells | PE | IgG2a κ | Q38-480 | Rat | 2 μg/mL | BD Pharmingen |
CD62L | BM inflamed cells | PE-Cy | IgG2a κ | MEL-14 | Rat | 4 μg/mL | BD Pharmingen |
CD31 | BM inflamed cells | PE | IgG2a κ | MEC 13.3 | Rat | 2 μg/mL | BD Pharmingen |
CCR2 | BM inflamed cells | PE | IgG2b | 475301 | Rat | 2 μg/mL | R&D systems |
CX3CR1 | Resident cells in BM | PE | IgG2a κ | SA011F11 | Mouse | 5 μg/mL | BioLegend |
Notes.
: PE: phycoerythrin; PE-Cy7: phycoerythrin-Cyanine 7
: Bp: Burkholderia pseudomallei
: poly: polyclonal antibodies